0.00Open0.03Pre Close0 Volume755 Open Interest122.00Strike Price0.00Turnover0.00%IV46.42%PremiumJan 3, 2025Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2778.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Money Thrill OP : Novo Nordisk climbed more than "3% in Copenhagen", following an upgrade of the pharmaceutical company's advice from 'neutral' to 'BUY', despite a sharply lowered target price from 1,100 to 750 Danish crowns. The broker lowered its target after CagriSema, but judged the wave of selling on the stock to be exaggerated. 'Novo remains the most exciting growth story in the EU pharmaceutical industry and is now reasonably valued,' it judges.